Company DescriptionPharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

How the Company Makes Money

Pharma Mar SA Financial Statement Overview

Summary

Pharma Mar SA is experiencing declining revenues and profitability, impacting its financial health. The balance sheet remains relatively strong with manageable leverage, but cash flow challenges pose a risk to financial stability. The company needs to focus on improving operational efficiency and cash flow generation to enhance its financial position.

Income Statement

Positive

Pharma Mar SA has shown a declining revenue trend over the past few years, with a notable decrease from 2020 to 2025. The TTM data shows a slight increase in total revenue compared to the previous year. The gross profit margin remains strong, indicating effective cost management, but the net profit margin has decreased significantly, reflecting reduced profitability. The EBIT and EBITDA margins have also declined, which indicates lower operational efficiency.

Balance Sheet

Positive

The company's balance sheet reflects a solid equity base with a strong equity ratio. The debt-to-equity ratio is manageable, signaling a balanced approach to leverage. However, the decrease in stockholders' equity over the years and fluctuations in total assets highlight potential concerns about asset management. The return on equity has decreased over time, reflecting challenges in generating returns for shareholders.

Cash Flow

Neutral

The cash flow statement shows significant variability, with negative free cash flow in the TTM period, indicating cash flow challenges. The operating cash flow to net income ratio is concerning, as it reflects difficulties in converting accounting profits into cash. However, the company has managed to maintain a positive operating cash flow in prior years, which suggests some potential for cash flow recovery.

TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
175.75M	174.85M	158.15M	196.34M	229.83M	269.96M
	Gross Profit
165.93M	166.67M	148.54M	182.70M	213.39M	256.24M
	EBIT
6.56M	6.47M	-3.83M	44.07M	92.45M	155.94M
	EBITDA
21.93M	21.23M	4.55M	52.07M	104.08M	155.94M
	Net Income Common Stockholders
19.88M	26.13M	1.14M	49.36M	92.86M	137.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
140.85M	154.53M	162.56M	182.42M	201.88M	195.52M
	Total Assets
333.50M	349.64M	340.52M	393.26M	368.39M	330.26M
	Total Debt
51.94M	51.08M	43.67M	42.63M	49.33M	56.66M
	Net Debt
-8.35M	-12.16M	-16.36M	-107.18M	-64.02M	-39.55M
	Total Liabilities
136.02M	141.28M	147.08M	170.30M	190.47M	227.54M
	Stockholders Equity
197.47M	208.36M	193.44M	222.96M	177.92M	102.72M
Cash Flow		Free Cash Flow
-18.29M	-9.48M	-29.40M	29.47M	17.87M	275.94M
	Operating Cash Flow
-9.56M	6.03M	-13.45M	38.32M	25.68M	278.94M
	Investing Cash Flow
39.33M	1.03M	-43.05M	10.88M	18.47M	-119.01M
	Financing Cash Flow
-5.43M	-5.35M	-32.14M	-13.37M	-27.41M	-73.82M

Pharma Mar SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHMMF		$1.72B	78.75	10.15%	0.73%	―	―
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
0O9B		€2.37B	232.50	0.69%	1.33%	―	―
0K9H		€1.34B	11.98	16.04%	2.97%	―	―
0RDV		€6.32B	26.84	3.37%	―	―	―
0RB1		€263.54M	23.59	5.11%	1.24%	―	―
0ILL		€2.80B	20.25	25.24%	1.62%	―	―

* Healthcare Sector Average

Performance Comparison

PHMMF

Pharma Mar SA

97.58

56.92

139.99%

GB:0O9B

Almirall

11.16

1.62

16.98%

GB:0K9H

Faes Farma

4.26

0.69

19.33%

GB:0RDV

Grifols

7.70

1.19

18.28%

GB:0RB1

LABORATORIO REIG JOFRE

3.19

0.13

4.25%

GB:0ILL

Laboratorios Farmaceuticos Rovi

55.76

-31.12

-35.82%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.